4.7 Review

Pathogenesis of asthma: implications for precision medicine

期刊

CLINICAL SCIENCE
卷 131, 期 14, 页码 1723-1735

出版社

PORTLAND PRESS LTD
DOI: 10.1042/CS20160253

关键词

-

资金

  1. AZ/Medimmune
  2. GSK
  3. Chiesi
  4. Novartis
  5. Regeneron
  6. Sanofi
  7. Gilead
  8. Glenmark
  9. TEVA
  10. BI
  11. Roche/Genentech
  12. Pfizer

向作者/读者索取更多资源

The pathogenesis of asthma is complex and multi-faceted. Asthma patients have a diverse range of underlying dominant disease processes and pathways despite apparent similarities in clinical expression. Here, we present the current understanding of asthma pathogenesis. We discuss airway inflammation (both T2(HIGH) and T2(LOW)), airway hyperresponsiveness (AHR) and airways remodelling as four key factors in asthma pathogenesis, and also outline other contributory factors such as genetics and co-morbidities. Response to current asthma therapies also varies greatly, which is probably related to the inter-patient differences in pathogenesis. Here, we also summarize how our developing understanding of detailed pathological processes potentially translates into the targeted treatment options we require for optimal asthma management in the future.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据